NAYA: NAYA Biosciences Corp P/S Multiple
NAYA Biosciences is accelerating the search for cancer therapies by utilizing robotic cell analysis systems. High R&D expenditures and stringent FDA oversight, combined with unique antibody patents, create significant barriers to entry for competitors. The company's price/sales multiple, which currently stands at 0.30, demonstrates that valuation is dependent on clinical trial results and investment inflows.
Analytical breakdowns for NAYA Bio (NAYA)
- stock price and consensus target price:
- market capitalization information:
- balance sheet equity data:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio NAYA Biosciences|NAYA - Long-Term Debt to Capital|Short-Term Debt to Equity NAYA Biosciences Corp|NAYA - Company Aggregate Debts|Debts to Net Assets NAYA Bio|NAYA - Company Long-Term Debt|Short-Term Debt NAYA Biosciences|Interim Coverage Ratio nayabiosciences.com
- earnings and multiples data:
NAYA - Net Profit|Future Profit NAYA Biosciences|NAYA - P/E Multiple|Market Cap to Projected Earnings NAYA Biosciences Inc|NAYA - PEG Multiple|Company Value to EBITDA NAYA Bio|NAYA - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months NAYA Biosciences|NAYA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months nayabiosciences.com|NAYA - Earnings growth in current year|Expected net earnings per share growth next year NAYA Biosciences
- issuer revenue and sales details:
General company analysis:NAYA, nayabiosciences.com
To assess long-term risks, the investor utilizes the P/S ratio, calculated as the ratio of market capitalization to annual sales, which reflects the cost of each unit of revenue. When analyzing the price-to-sales chart, it should be noted that for NAYA Biosciences (NAYA), this metric is speculative in nature due to the lack of mass-market sales prior to the completion of clinical trials and the procurement of licenses.
Competitors of NAYA Biosciences
beigene.com - Market Cap to Revenue Ratio|P/S Multiple HALO (Halozyme)|P/S Multiple Revolution Medicines Inc RVMD|AAPG: Market Cap to Revenue|Price to Sales CG Oncology Therapeutics|URGN: P/S Multiple|bicara.com (BCAX) - P/S Multiple|Market Cap to Revenue PSNL|ERAS: Market Capitalization-to-Revenue Ratio|P/S Multiple DCTH|Price-to-Revenue Ratio YMAB (Y-mAbs Corp)|P/S Multiple AURA (Aura Biosciences, Inc.)|Price-to-Revenue Coefficient Candel Therapeutics Inc. (CADL)|ARAY - Price-to-Revenue Ratio|Price to Sales SELLAS Life Sciences|Actuate Therapeutics, Inc (ACTU) - Price-to-Revenue Ratio|CTOR - Price-to-Revenue Coefficient|HURA (TuHURA Biosciences Inc.) - P/S Multiple|Market Cap to Revenue protaratx.com (TARA)|P/S Multiple FATE|Price-to-Revenue Coefficient aadibio.com|P/S Multiple TCRX (TScan Therapeutics, Inc.)|Champions Oncology Inc (CSBR) - Price to Sales|XBIT - Price-to-Revenue Ratio|CVM (CEL-SCI Corporation) - Market Cap to Revenue Ratio|OSTX: P/S Multiple|Market Cap to Revenue radiopharmtheranostics.com|ARTV (Artiva Biotherapeutics Inc.) - P/S Multiple|Price to Sales Adlai Nortye Limited ANL|Price-to-Revenue Ratio Veru Inc. (VERU)|Price-to-Revenue Coefficient tempesttx.com|Price-to-Revenue Ratio Xilio Therapeutics XLO|RENB: Market Cap to Revenue Ratio|Mural Bio - P/S Multiple|KAPA - P/S Multiple|OKUR (onkuretherapeutics.com) - Market Cap to Revenue|Price to Sales CytoMed Therapeutics Limited (GDTC)|CRIS (Curis Inc.) - P/S Multiple|P/S Multiple Apollomics Corp|P/S Multiple THAR|Market Cap to Revenue advanbiomed.com ADVB|P/S Multiple GNPX (Genprex, Inc.)|P/S Multiple Calidi Biotherapeutics Inc. CLDI|SBFM - Price-to-Revenue Ratio|XBIO (Xenetic Biosciences) - Market Cap to Revenue Ratio|SLRX: P/S Multiple|Market Cap to Revenue Kitov Pharma|AONC (American Oncology Network Inc) - P/S Multiple|Price to Sales beigene.com BGNE|Price-to-Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|ELEV (elevationoncology.com) - Market Capitalization-to-Revenue Ratio|iCAD - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IKNA|Notable Labs, Ltd. - P/S Multiple|Viracta Therapeutics (VIRX) - Market Cap to Revenue|MOR (MorphoSys) - Market Cap to Revenue|Ascentage Pharma Group International (AAPGV) - P/S Multiple
